{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:41:00Z","timestamp":1768545660754,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chk1 kinase inhibitors are currently under clinical investigation as potentiators of cytotoxic chemotherapy and demonstrate potent activity in combination with anti-metabolite drugs that increase replication stress through the inhibition of nucleotide or deoxyribonucleotide biosynthesis. Inhibiting other metabolic pathways critical for the supply of building blocks necessary to support DNA replication may lead to increased DNA damage and synergy with an inhibitor of Chk1. A screen of small molecule metabolism modulators identified combinatorial activity between a Chk1 inhibitor and chloroquine or the LDHA\/LDHB inhibitor GSK 2837808A. Compounds, such as 2-deoxyglucose or 6-aminonicotinamide, that reduced the fraction of cells undergoing active replication rendered tumour cells more resistant to Chk1 inhibitor-induced DNA damage. Withdrawal of glucose or glutamine induced G1 and G2\/M arrest without increasing DNA damage and reduced Chk1 expression and activation through autophosphorylation. This suggests the expression and activation of Chk1 kinase is associated with cells undergoing active DNA replication. Glutamine starvation rendered tumour cells more resistant to Chk1 inhibitor-induced DNA damage and reversal of the glutamine starvation restored the sensitivity of tumour cells to Chk1 inhibitor-induced DNA damage. Chk1 inhibitors may be a potentially useful therapeutic treatment for patients whose tumours contain a high fraction of replicating cells.<\/jats:p>","DOI":"10.1038\/srep40778","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T12:01:10Z","timestamp":1484913670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage"],"prefix":"10.1038","volume":"7","author":[{"given":"Andrew J.","family":"Massey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"BFsrep40778_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrd4553","volume":"14","author":"M Dobbelstein","year":"2015","unstructured":"M. Dobbelstein & C. S. Sorensen . Exploiting replicative stress to treat cancer. Nat. Rev. Drug Discov. 14(6), 405 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFsrep40778_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2217\/fon.15.292","volume":"12","author":"EM Taylor","year":"2016","unstructured":"E. M. Taylor & H. D. Lindsay . DNA replication stress and cancer: cause or cure? Future. Oncol. 12(2), 221 (2016).","journal-title":"Future. Oncol."},{"key":"BFsrep40778_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"H. Gaillard, T. Garcia-Muse & A. Aguilera . Replication stress and cancer. Nat. Rev. Cancer 15(5), 276 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"BFsrep40778_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.4161\/cc.9.6.11155","volume":"9","author":"Y Dai","year":"2010","unstructured":"Y. Dai & S. Grant . Targeting Chk1 in the replicative stress response. Cell Cycle 9(6), 1025 (2010).","journal-title":"Cell Cycle"},{"key":"BFsrep40778_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ijc.28226","volume":"134","author":"Y Zhang","year":"2014","unstructured":"Y. Zhang & T. Hunter . Roles of Chk1 in cell biology and cancer therapy. Int. J. Cancer 134(5), 1013 (2014).","journal-title":"Int. J. Cancer"},{"key":"BFsrep40778_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mrrev.2014.10.003","volume":"763","author":"MA Gonzalez Besteiro","year":"2015","unstructured":"M. A. Gonzalez Besteiro & V. Gottifredi . The fork and the kinase: a DNA replication tale from a CHK1 perspective. Mutat. Res. Rev. Mutat. Res. 763, 168 (2015).","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"BFsrep40778_CR7","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1128\/MCB.01611-06","volume":"27","author":"H Niida","year":"2007","unstructured":"H. Niida et al. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol. Cell Biol. 27(7), 2572 (2007).","journal-title":"Mol. Cell Biol."},{"key":"BFsrep40778_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1747-1028-4-8","volume":"4","author":"C Tapia-Alveal","year":"2009","unstructured":"C. Tapia-Alveal, T. M. Calonge & M. J. O\u2019Connell . Regulation of chk1. Cell Div. 4, 8 (2009).","journal-title":"Cell Div."},{"key":"BFsrep40778_CR9","doi-asserted-by":"publisher","first-page":"8808","DOI":"10.1074\/jbc.M312215200","volume":"279","author":"CP Ng","year":"2004","unstructured":"C. P. Ng et al. Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J. Biol. Chem. 279(10), 8808 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFsrep40778_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4161\/cc.4.1.1299","volume":"4","author":"SH Cho","year":"2005","unstructured":"S. H. Cho et al. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4(1), 131 (2005).","journal-title":"Cell Cycle"},{"key":"BFsrep40778_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.840500","volume":"14","author":"Q Liu","year":"2000","unstructured":"Q. Liu et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint. Genes Dev. 14(12), 1448 (2000).","journal-title":"Genes Dev."},{"key":"BFsrep40778_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","volume":"142","author":"S McNeely","year":"2014","unstructured":"S. McNeely, R. Beckmann & A. K. Bence Lin . CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol. Ther. 142(1), 1 (2014).","journal-title":"Pharmacol. Ther."},{"key":"BFsrep40778_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.drudis.2011.12.009","volume":"17","author":"T Chen","year":"2012","unstructured":"T. Chen et al. Targeting the S and G2 checkpoint to treat cancer. Drug Discov. Today 17(5\u20136), 194 (2012).","journal-title":"Drug Discov. Today"},{"key":"BFsrep40778_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"D. Hanahan & R. A. Weinberg . Hallmarks of cancer: the next generation. Cell 144(5), 646 (2011).","journal-title":"Cell"},{"key":"BFsrep40778_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"R. A. Cairns, I. S. Harris & T. W. Mak . Regulation of cancer cell metabolism. Nat. Rev. Cancer 11(2), 85 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"BFsrep40778_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"P. P. Hsu & D. M. Sabatini . Cancer cell metabolism: Warburg and beyond. Cell 134(5), 703 (2008).","journal-title":"Cell"},{"key":"BFsrep40778_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","volume":"35","author":"DR Wise","year":"2010","unstructured":"D. R. Wise & C. B. Thompson . Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35(8), 427 (2010).","journal-title":"Trends Biochem. Sci."},{"key":"BFsrep40778_CR18","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/1535-7163.MCT-13-0404","volume":"12","author":"Y Xiao","year":"2013","unstructured":"Y. Xiao et al. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. Mol. Cancer Ther. 12(11), 2285 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"BFsrep40778_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.18632\/aging.100284","volume":"3","author":"CE Redon","year":"2011","unstructured":"C. E. Redon et al. Recent developments in the use of gamma-H2AX as a quantitative DNA double-strand break biomarker. Aging (Albany. NY) 3(2), 168 (2011).","journal-title":"Aging (Albany. NY)"},{"key":"BFsrep40778_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1476-4598-13-147","volume":"13","author":"C Bryant","year":"2014","unstructured":"C. Bryant, K. Scriven & A. J. Massey . Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells. Mol. Cancer 13(1), 147 (2014).","journal-title":"Mol. Cancer"},{"key":"BFsrep40778_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/1471-2407-14-570","volume":"14","author":"C Bryant","year":"2014","unstructured":"C. Bryant, R. Rawlinson & A. J. Massey . Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC. Cancer 14, 570 (2014).","journal-title":"BMC. Cancer"},{"key":"BFsrep40778_CR22","doi-asserted-by":"publisher","first-page":"35797","DOI":"10.18632\/oncotarget.5929","volume":"6","author":"AJ Massey","year":"2015","unstructured":"A. J. Massey et al. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. Oncotarget. 6(34), 35797 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep40778_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/1471-2407-14-483","volume":"14","author":"R Rawlinson","year":"2014","unstructured":"R. Rawlinson & A. J. Massey . gammaH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. BMC. Cancer 14(1), 483 (2014).","journal-title":"BMC. Cancer"},{"key":"BFsrep40778_CR24","doi-asserted-by":"publisher","first-page":"25485","DOI":"10.1074\/jbc.M803111200","volume":"283","author":"K Matsuura","year":"2008","unstructured":"K. Matsuura et al. Cleavage-mediated activation of Chk1 during apoptosis. J. Biol. Chem. 283(37), 25485 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFsrep40778_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4161\/cc.27055","volume":"13","author":"CJDel Nagro","year":"2014","unstructured":"C. J. Del Nagro et al. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. Cell Cycle 13(2), 303 (2014).","journal-title":"Cell Cycle"},{"key":"BFsrep40778_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1073\/pnas.1409563112","volume":"112","author":"EY Liu","year":"2015","unstructured":"E. Y. Liu et al. Loss of autophagy causes a synthetic lethal deficiency in DNA repair. Proc. Natl. Acad. Sci. USA 112(3), 773 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep40778_CR27","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10495-014-1010-3","volume":"19","author":"FZ Wang","year":"2014","unstructured":"F. Z. Wang et al. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Apoptosis. 19(9), 1389 (2014).","journal-title":"Apoptosis."},{"key":"BFsrep40778_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2049-3002-1-19","volume":"1","author":"J Billiard","year":"2013","unstructured":"J. Billiard et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab 1(1), 19 (2013).","journal-title":"Cancer Metab"},{"key":"BFsrep40778_CR29","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.bbalip.2015.06.001","volume":"1851","author":"SanchezC Martin","year":"2015","unstructured":"Sanchez C. Martin et al. Disruption of the mevalonate pathway induces dNTP depletion and DNA damage. Biochim. Biophys. Acta 1851(9), 1240 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFsrep40778_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"H. Gad et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508(7495), 215 (2014).","journal-title":"Nature"},{"key":"BFsrep40778_CR31","doi-asserted-by":"publisher","first-page":"e0134306","DOI":"10.1371\/journal.pone.0134306","volume":"10","author":"AJ Massey","year":"2015","unstructured":"A. J. Massey . Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC. PLoS. One. 10(7), e0134306 (2015).","journal-title":"PLoS. One."},{"key":"BFsrep40778_CR32","doi-asserted-by":"crossref","unstructured":"G. Y. Di Veroli et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics., doi: 10.1093\/bioinformatics\/btw230 (2016).","DOI":"10.1093\/bioinformatics\/btw230"},{"key":"BFsrep40778_CR33","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1126\/science.1120781","volume":"310","author":"RJ Shaw","year":"2005","unstructured":"R. J. Shaw et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754), 1642 (2005).","journal-title":"Science"},{"key":"BFsrep40778_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"K. C. Patra & N. Hay . The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39(8), 347 (2014).","journal-title":"Trends Biochem. Sci."},{"key":"BFsrep40778_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature10167","volume":"475","author":"L Raj","year":"2011","unstructured":"L. Raj et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475(7355), 231 (2011).","journal-title":"Nature"},{"key":"BFsrep40778_CR36","doi-asserted-by":"crossref","first-page":"12862","DOI":"10.18632\/oncotarget.2656","volume":"5","author":"JD Moore","year":"2014","unstructured":"J. D. Moore et al. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget. 5(24), 12862 (2014).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep40778.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40778","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40778.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T21:47:52Z","timestamp":1671832072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep40778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,13]]}},"alternative-id":["BFsrep40778"],"URL":"https:\/\/doi.org\/10.1038\/srep40778","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]},"assertion":[{"value":"21 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AJM is currently an employee and stock option holder of Vernalis Research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40778"}}